New drug 608 aims to ease back pain in ankylosing spondylitis

NCT ID NCT07261644

Recruiting now Disease control Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests an experimental drug called 608 in 500 adults with active ankylosing spondylitis (AS), a type of arthritis that causes back pain and stiffness. Participants receive either 608 injections or a placebo. The main goal is to see if 608 improves symptoms like pain and mobility better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 608 (an experimental drug given as a subcutaneous injection)
What this could lead to: If successful, this could provide a new treatment option to reduce pain and stiffness in people with active ankylosing spondylitis.
What could go wrong: This is an early Phase 3 trial, so results may not confirm benefit. The drug could have side effects or fail to outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANKYLOSING SPONDYLITIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site 01
RECRUITING

Beijing, Beijing Municipality, 100730, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.